Chan Kim

Assistant Professor

CHA University School of Medicine

South Korea

Research Interests

Explore related searches

Professors in South Korea Professors in Immunology Immunology professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Chan Kim is an Assistant Professor at CHA University School of Medicine, South Korea. His research primarily focuses on tumor immunity, colorectal cancer, and genomic profiling in biliary tract cancer, as evidenced by his recent publications. He is actively involved in investigating therapeutic strategies that enhance antitumor immunity and address treatment resistance in various forms of cancer.

Articles (16)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

UNITED STATES

View details

ilhwan kim

Associate Professor

Inje University Ilsan Paik Hospital

SOUTH KOREA

View details

Sanghoon Jung

Assistant Professor

CHA Bundang Medical Center

SOUTH KOREA

View details

Wooram Park

Assistant Professor

Sungkyunkwan University

SOUTH KOREA

View details

Hannah Yang

University of Michigan

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Chan Kim

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Reply to: Correspondence on ‘Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer’

Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab

Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance

Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer

Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer

Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.

ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer

High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma—Reply

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.

Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab

High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer.

Collaborators (9)

Seul-Gi Kim

Han Sang Kim

Hong Jae Chon

Sung Hwan Lee

Ilona Kryczek

ilhwan kim

Sanghoon Jung

Wooram Park

Hannah Yang

Make your next move.